Y-mAbs Therapeutics (NASDAQ:YMAB) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPS

Y-mAbs Therapeutics (NASDAQ:YMAB) issued its earnings results on Monday. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.08), Zacks reports. Y-mAbs Therapeutics had a negative net margin of 25.64% and a negative return on equity of 21.40%. The company had revenue of $22.80 million during the quarter, compared to analyst estimates of $23.09 million. During the same quarter in the previous year, the company posted ($0.14) EPS. Y-mAbs Therapeutics updated its FY 2024 guidance to EPS.

Y-mAbs Therapeutics Stock Performance

Y-mAbs Therapeutics stock traded up $0.75 during trading hours on Wednesday, reaching $11.57. 131,961 shares of the stock were exchanged, compared to its average volume of 358,216. The stock has a market cap of $507.73 million, a P/E ratio of -23.86 and a beta of 0.66. Y-mAbs Therapeutics has a 52-week low of $4.69 and a 52-week high of $20.90. The firm’s 50 day moving average is $11.86 and its 200 day moving average is $13.73.

Analyst Ratings Changes

Several analysts recently commented on the stock. Canaccord Genuity Group reiterated a “buy” rating and issued a $26.00 price target on shares of Y-mAbs Therapeutics in a research report on Tuesday. Wedbush reiterated an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a research report on Monday. Morgan Stanley reduced their price target on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a research report on Tuesday. BMO Capital Markets reduced their price target on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a research report on Tuesday. Finally, Canaccord Genuity Group upgraded shares of Y-mAbs Therapeutics to a “strong-buy” rating in a research report on Tuesday. Two investment analysts have rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $19.29.

Insiders Place Their Bets

In other news, CFO Bo Kruse sold 31,371 shares of the company’s stock in a transaction on Friday, May 31st. The shares were sold at an average price of $12.07, for a total transaction of $378,647.97. Following the transaction, the chief financial officer now directly owns 210,877 shares of the company’s stock, valued at approximately $2,545,285.39. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, CFO Bo Kruse sold 31,371 shares of the company’s stock in a transaction on Friday, May 31st. The shares were sold at an average price of $12.07, for a total transaction of $378,647.97. Following the transaction, the chief financial officer now directly owns 210,877 shares of the company’s stock, valued at approximately $2,545,285.39. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Thomas Gad sold 7,351 shares of the stock in a transaction dated Thursday, May 23rd. The shares were sold at an average price of $13.00, for a total transaction of $95,563.00. Following the completion of the sale, the insider now directly owns 232,681 shares in the company, valued at $3,024,853. The disclosure for this sale can be found here. In the last quarter, insiders sold 99,444 shares of company stock worth $1,203,925. 21.50% of the stock is owned by insiders.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.